Drug Store News - Biovail to market Cardizem
Saturday, December 20th, 2008 Biovail Corp. has purchased the rights to market the Cardizem line of calcium channel blockers in North America from Aventis. Biovail will pay Aventis $409.5 million. Aventis will continue to manufacture the Cardizem line.
The Cardizem product line includes Cardizem CD (diltiazem) for hypertension…
